MK-677 Half-Life: What Human Studies Actually Establish
MK-677, also called ibutamoren or MK-0677, is an investigational, orally active, non-peptide agonist of the ghrelin receptor. Calling it a peptide is chemically incorrect.
The often-repeated claim that MK-677 has a 24-hour human plasma half-life is not established by the human papers cited on the previous version of this page. Those trials show pharmacodynamic activity across a 24-hour period and effects after daily administration, but that is not the same measurement as a terminal elimination half-life.
Half-life and effect duration are different
Plasma half-life describes how quickly measured drug concentration declines. Pharmacodynamic duration describes how long a biological effect persists. For MK-677, published human trials clearly show changes in GH and IGF-1 after oral administration. A sustained biomarker response does not prove that the parent compound remains in plasma with a 24-hour terminal half-life.
This distinction matters because the previous page used the 24-hour number to generate dosing, steady-state, clearance, and washout instructions. Those calculations inherit the uncertainty of the starting value and should not be presented as established human pharmacokinetics.
What PMID 10404019 actually reports
The paper previously cited as the primary human half-life source studied daily oral MK-677 in older adults and reported changes in bone-turnover markers, GH, and IGF-1. Its public abstract does not report a measured 24-hour terminal plasma half-life. It therefore cannot support the previous claim that this number came from serial steady-state plasma pharmacokinetic sampling.
What the human studies do support
Human trials support the following narrower statements:
MK-677 is orally active;
single and repeated administration can increase GH-related measurements;
repeated administration can increase IGF-1 in studied populations;
clinical studies have used once-daily administration;
pharmacodynamic effects and safety signals have been observed over periods longer than a single dose.
These observations do not resolve the exact terminal half-life in humans.
Animal values should not be relabeled as human values
A 4-to-6-hour figure is often attributed to beagle-dog pharmacokinetic data. An animal value may help preclinical interpretation, but it should not be presented as a human estimate without a validated translation model.
Unsupported claims removed from this page
The current evidence reviewed here does not justify fixed statements that:
human terminal half-life is approximately 24 hours;
steady state is reached in three to five days;
plasma washout is complete in five days;
IGF-1 normalizes in one to two weeks;
a particular administration time optimizes results;
a specific sampling or monitoring schedule applies generally.
Those may be research questions or protocol-specific choices, but they are not established by the cited sources.
Research and sourcing questions
MK-677 is a small molecule rather than a peptide. Identity testing and impurity analysis should therefore match the compound and synthesis route. Useful documentation may include chromatographic purity, mass-spectrometric identity, residual-solvent testing, water content, salt-form confirmation, and batch traceability. A generic peptide COA template is not sufficient.
FAQ
Is MK-677 a peptide?
No. MK-677 is a non-peptide small-molecule ghrelin-receptor agonist and growth-hormone secretagogue.
Is its human plasma half-life proven to be 24 hours?
The human studies cited on the previous page do not establish a measured 24-hour terminal plasma half-life. They show sustained pharmacodynamic effects and use of daily administration.
Does a 24-hour IGF-1 or GH effect equal a 24-hour drug half-life?
No. Biomarker duration and parent-drug plasma elimination are different measurements.
Can the beagle-dog half-life be used as the human half-life?
No. Animal pharmacokinetics should remain labeled as animal data.
Does this article provide dosing or washout guidance?
No. The previous dosing and washout calculations were removed because their key pharmacokinetic premise was not adequately supported.
References
Murphy MG, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research. 1999. PMID 10404019. https://pubmed.ncbi.nlm.nih.gov/10404019/
Murphy MG, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology and Metabolism. 1998. PMID 9467534. https://pubmed.ncbi.nlm.nih.gov/9467534/
FDA Pharmacy Compounding Advisory Committee materials concerning ibutamoren. October 29, 2024. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/2024-meeting-materials-pharmacy-compounding-advisory-committee
Research-use notice: MK-677 is investigational. This page provides no dosing, administration, monitoring, or washout instructions.